Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 25, 2026, titled "Zydus plans to launch innovative Semaglutide Injection in India on Day 1 of patent expiry, expanding patient access to GLP-1 therapy".
Press Release Feb 25 2026
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release regarding the launch of an innovative Semaglutide Injection in India, coinciding with the patent expiry of the drug. The injection will be marketed under the brand names SEMAGLYN, MASHEMA, and ALTERME, and features a novel drug delivery system that enhances patient convenience and adherence. This initiative aims to address the growing health concerns related to diabetes and obesity in India, which affect a significant portion of the adult population.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Feb 19 2026
- Press Release Feb 18 2026
- Press Release Feb 17 2026
- Press Release Feb 14 2026
- Press Release 10-02-2026 NewspaperPublication10022026
Later from Zydus Lifesciences
- Press Release Feb 27 2026
- Press Release Feb 28 2026
- Press Release Mar 12 2026
- Press Release Mar 13 2026
- Press Release Mar 14 2026
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences